Islet Sciences to Develop Diabetes Diagnostic Using Droplet-based Digital PCR | GenomeWeb

NEW YORK (GenomeWeb) — Islet Sciences, a Raleigh, NC-based biopharmaceutical company, said yesterday that its collaborators at Yale University School of Medicine have published key data demonstrating the efficacy of a novel droplet-based digital PCR (ddPCR) diabetes diagnostic.

Islet holds an exclusive license to the epigenetic test, which detects methylation status of cell-free DNA in order to track pancreatic beta cell death. Company representatives said this week that Islet intends to commercialize this assay by 2015.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genetic method to gauge age of ancient samples, genetic polymorphisms in mouse strain, and more.

Two Stanford professors are turning to the online game EteRNA to develop a new way to diagnose tuberculosis.

Lita Nelsen from the Massachusetts Institute of Technology's technology-transfer office is retiring after decades there.

After nine years, the Canadian government is loosening its restrictions on government scientists' ability to speak to the press and public.